Trial Profile

Thorough QT study of ELND 005 in volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELND 005 (Primary) ; Moxifloxacin
Indications Alzheimer's disease; Bipolar disorders; Cognition disorders
Focus Adverse reactions
Sponsors Transition Therapeutics

Most Recent Events

15 Jan 2015 New trial record
24 Nov 2014 Results published in Transition Therapeutics media release.
24 Nov 2014 Results data were presented at Clinical Trials in Alzheimer's Disease conference on November 2014, according to a Transition Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com